Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Sanofi-Aventis profits rise 53.6 percent on Exubera licence sale
- PARIS AFP — Pharmaceutical group Sanofi-Aventis has reported that first-quarter net profit had surged by 53.6 percent with a big injection from the sale of the patent for diabetes treatment Exubera to US group Pfizer. Net profit amounted to 2.173 billion euros (2.76 billion dollars), far above the figure...
- Research articles 2006-05-05
- Mannkind entering fray over inhaled insulin market
- MannKind Corp. marched into the American Diabetes Association's 65th annual Scientific Sessions last week looking a little bit like an underdog. But despite the fact that rival pharmaceutical companies are likely to beat MannKind to the market with competing insulin delivery products, the Valencia-based company has plenty of reasons...
- Research articles 2005-06-20
- US FDA accepts diabetes drug application by Sanofi-Aventis, Pfizer
- PARIS AFP — The US Food and Drug Administration has accepted a new drug application by French pharmaceutical group Sanofi-Aventis and Pfizer of the United States for Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, the companies said. The companies want...
- Research articles 2005-03-02
- In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics
- As companies bail out of the inhaled insulin business -- most recently Pfizer, which lost $2.8 billion before throwing Exubera overboard -- one small firm believes there is an alternative to pills, injections and inhalers. Generex, a Worcester, Mass.-based company, believes there's an opportunity for insulin delivery...
- Blog posts 2008-09-26
- In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics
- In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for DiabeticsRE: In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics..."What do you think?"...well, right now I think you are either one dumb, gullible SOB or else you're on GNBT's payroll...absorption of oralyn's insulin is...
- Discussion threads 2008-10-01
Additional Resources
- Exubera market performance predicted to disappoint Pfizer stakeholders, according to Business Week article by healthcare experts at The Bruckner Group
- WAKEFIELD, Mass. -- At launch, Exubera lacks the necessary profile for success in today's evidence-based, payer-dominated market, according to "Irrational Exubera-nce for Pfizer," an article published today in Business Week online. Drawing upon the 2006 Bruckner Group BGI Payer Study, BGI's Outcomes-Based Access OBA Index, and BGI's outcomes-based access database,...
- Research articles 2006-02-15
- Pfizer's Exubera(R): A Unique Background Perspective
- 40 million diabetics in the United States and Europe could benefit from the Food and Drug Administration's approval today of Exubera®, an inhaled form of insulin. Plexus Ventures, an independent pharmaceutical business development firm based in Philadelphia, PA, assisted Nektar Therapeutics, then Inhale Therapeutic Systems, in partnering with Pfizer Inc...
- Research articles 2006-01-27
- Nektar Reports that Pfizer Inc and sanofi-aventis Announce Data Presented at American Diabetes Association Scientific Sessions Support Exubera Efficacy and Safety Profile in Type 1 and Type 2 Diabetes
- SAN DIEGO -- Results from three two-year studies presented at the 65th Annual Scientific Sessions of the American Diabetes Association showed that ExuberaR human insulin powder, an inhaleable, short-acting, dry powder insulin, provided effective, sustained glycemic control and was well tolerated over two years in adults with type 2 diabetes....
- Research articles 2005-06-14
- Nektar Reports that Pfizer and The Sanofi-Aventis Group Seek Approval to Market Exubera in the United States
- SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) today reported that Pfizer Inc and The Sanofi-Aventis Group announced that the United States Food and Drug Administration FDA has accepted for filing a new drug application for ExuberaR inhaled human insulin powder. Nektar develops and provides the inhalers and the powdered insulin...
- Research articles 2005-03-02
- PFIZER INC - Statement re (Exubera Trial).
- Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera NEW YORK, Dec. 14 -- Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that wo...
- Research articles 2006-12-14
- Pfizer Statement on Exubera Labeling Update in the United States
- NEW YORK -- Pfizer Inc said today that it updated the US product labeling for EXUBERA[R] (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera.
- Research articles 2008-04-09
- Nektar Reports That Pfizer to Introduce Exubera in U.S. With a Comprehensive Education Program
- SAN CARLOS, Calif. -- Education and Training Program to Begin in July; Initial Supplies of Exubera to Be Available Across U.S. Beginning in September; Nektar Increases Guidance for Exubera Revenue
- Research articles 2006-07-20
- BioSante Encouraged by FDA Panel on Exubera, Superior Results of Own Inhaled Insulin Study
- LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (Amex:BPA) today expressed encouragement by the U.S. Food & Drug Administration FDA Advisory Panel's recommended approval of Pfizer, Inc.'s Exubera inhaled insulin therapy, and noted superior results in preclinical studies with its own inhalable insulin delivery system.
- Research articles 2005-09-21
- Nektar Therapeutics Reports Exubera® Receives Positive Opinion from CHMP for the Treatment of Type 1 and Type 2 Diabetes
- SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) today reported that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Evaluation Agency EMEA has issued a positive opinion recommending approval of ExuberaR insulin human, an inhaleable form of insulin for the treatment of type 1 and type...
- Research articles 2005-10-13
- Nektar Reports That FDA Advisory Committee Recommends Approval of Exubera® for Use in Adults with Type 1 and Type 2 Diabetes
- SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) today reported that Pfizer Inc and the sanofi-aventis Group said that a U.S. Food and Drug Administration FDA advisory committee panel has recommended the approval of ExuberaR (insulin rDNA origin powder for oral inhalation), an inhaleable, rapid-acting, dry powder insulin for the treatment...
- Research articles 2005-09-08
- Pfizer pfudges with its withdrawl of Exubera
- PFIZER AND Nektar have buried the hatchet after the former paid the latter $135 million following its abrupt decision to discontinue marketing of Exubera, on which the two firms partnered. But Pfizer's handling of the matter could do lasting damage to the company's reputation-particularly among its prospective partners.
- Research articles 2007-12-01
- The Demise of Pfizer's Exubera Predicted in February 2006 in BusinessWeek by The Bruckner Group
- WAKEFIELD, Mass. -- Yesterday's announcement that Pfizer is taking a $2.8 billion charge and scrapping Exubera, its inhaled insulin therapy, was predicted in mid-2005 and published in BusinessWeek on February 15, 2006 in an article written by Bruckner Group partners Michael J. Russo and David Balekdjian. Here is a link...
- Research articles 2007-10-18
- Pfizer and Nektar Reach Agreement on Exubera®
- NEW YORK & SAN CARLOS, Calif. -- Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera[R] and Nektar's innovative Next Generation Inhaled Insulin NGI product currently in Phase 1 clinical development.
- Research articles 2007-11-13
- Nektar Reports That Nasdaq Halted Trading of Nektar Common Stock Today; FDA Advisory Committee Meeting to Discuss Exubera® Powder for Oral Inhalation
- SAN CARLOS, Calif. -- Nektar Therapeutics (Nasdaq:NKTR) announced that Nasdaq has halted trading of Nektar common stock today, Thursday, September 8, 2005. The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration FDA meets today to review and discuss the New Drug Application NDA for ExuberaR...
- Research articles 2005-09-08
- Pfizer Burns More Money on the Inhaled Insulin Bonfire
- After burning $2.8 billion, Pfizer is throwing yet more money on the inhaled insulin bonfire. The company's announcement that it has a deal to switch former Exubera patients to MannKind's TechnoSphere is a real head-scratcher. One unanswered question is, exactly how many Exubera patients are there? Pfizer...
- Blog posts 2008-09-18
- << Previous
- page 1 of 1
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
